At present, it is reasonable to conclude that very individualized therapies, taking into account interactions of angiotensin peptides, vasopressin, and insulin, should be selected for patients suffering from co-existing cardiovascular and metabolic diseases. This evidence concerns the gene INS and Other metabolic disease.